Filing identity and reporting period
Important mismatch: The supplied filing is MEI Pharma, Inc.’s unaudited Form 10-Q for the three months ended September 30, 2022, not a Lite Strategy, Inc. filing for 2021 Q1. The summary below reflects the source document.
Business context
MEI Pharma is a clinical-stage cancer drug developer. Its pipeline includes zandelisib, voruciclib and ME-344. The quarter is the first quarter of the company’s fiscal year ending June 30, 2023. The filing reports no commercial product sales; revenue primarily reflects its collaboration with Kyowa Kirin Co., Ltd. (KKC).
Financial results and liquidity
| Metric | Quarter ended Sep. 30, 2022 | Comparable 2021 quarter |
|---|---|---|
| Revenue | $8.7 million | $7.8 million |
| Research and development | $19.5 million | $20.0 million |
| General and administrative | $7.5 million | $7.9 million |
| Operating loss | $18.2 million | $20.1 million |
| Net loss | $16.6 million | $17.5 million |
| Net cash used in operating activities | $14.8 million | $7.7 million |
Revenue rose about 13%; net loss narrowed about 5%. The loss improvement included a $1.1 million noncash gain from revaluing warrants and $0.5 million of interest and dividend income. No gross margin is presented. Operating cash use increased, partly because the prior-year quarter included a $10 million KKC milestone receipt.
At September 30, 2022, cash, cash equivalents and short-term U.S. government investments totaled $138.4 million, down from $153.3 million at June 30. Current assets were $148.9 million and current liabilities $23.4 million. Total liabilities were $126.3 million, including $94.5 million of KKC-related deferred revenue and $13.7 million of operating lease liabilities. The filing does not report borrowings or funded debt. Accumulated deficit was $390.8 million. Management said available resources should fund operations for at least 12 months from issuance, while anticipating continued losses, negative operating cash flows and a future need for financing or partnerships.
Material changes, outlook and risks
- Zandelisib regulatory path: Following FDA feedback and broader concerns about PI3Kδ inhibitor safety, the company no longer planned to seek approval based on the single-arm Phase 2 TIDAL study. It is relying on the randomized Phase 3 COASTAL study to support potential U.S. and global applications.
- Trial enrollment and supply: COVID-19 and the Russia-Ukraine conflict adversely affected COASTAL enrollment. A packaging and labeling supply issue required a pause in new-patient enrollment in COASTAL and CORAL pending regulatory review and replacement supplies; management estimated about a three-month delay to COASTAL enrollment completion.
- Pipeline plans: Management expected to begin a Phase 1 voruciclib-plus-venetoclax study in AML by year-end 2022 and planned a Phase 1b ME-344 study with bevacizumab in relapsed colorectal cancer in the first half of 2023. These are forward-looking plans, not reported outcomes.
- KKC collaboration: KKC paid $100 million upfront and two $10 million milestones had been received in fiscal 2022. The agreement includes potential additional milestones of up to approximately $582.5 million and ex-U.S. royalties; these contingent amounts are not assured.
- Nasdaq listing: The share price was below the $1 minimum bid-price requirement. Nasdaq granted an extension through May 8, 2023; the company had not regained compliance when the financial statements were issued.
- Controls: Management said disclosure controls were ineffective due to a material weakness in controls over accounting for license-agreement revenue recognition. Remediation was underway, with no assurance it would be effective.
- Other risks: Clinical efficacy and safety remain uncertain; the FDA has raised benefit-risk concerns for the PI3Kδ inhibitor class. The company also cited clinical-trial, manufacturing, financing, competitive and regulatory risks. No legal proceedings were reported in this filing.
Important facts for investors to verify
- Confirm the intended issuer and period: the source is MEI Pharma’s September 2022 quarter, not Lite Strategy’s 2021 Q1.
- Check subsequent FDA and clinical-trial developments for zandelisib, including COASTAL enrollment, supply resolution and any change in the regulatory strategy.
- Assess cash burn against the $138.4 million liquidity balance and management’s 12-month runway statement; future R&D costs and capital needs are uncertain.
- Monitor Nasdaq bid-price compliance and potential dilution: 133.3 million common shares were outstanding as of November 10, 2022, alongside 16.1 million warrants and substantial outstanding options.
- Review whether the revenue-recognition control weakness was remediated and whether any further restatements or control issues were disclosed.